Chemomab Therapeutics

Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for fibro-inflammatory diseases with a high unmet medical need. Their lead compound, CM-101, is a first-in-class humanized monoclonal antibody designed to neutralize the activity of the soluble protein CCL24, which plays a pivotal role in promoting fibrosis and inflammation. CM-101 has demonstrated promising anti-fibrotic, anti-inflammatory, and anti-cholestatic effects in preclinical studies and is currently being evaluated in Phase 2 clinical trials for primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc).

Chemomab has a strong track record of scientific discovery and clinical development, with their research highlighting the importance of CCL24 as a key target for treating fibro-inflammatory diseases. The company has achieved significant milestones, including positive Phase 2 results for CM-101 in PSC, and is actively seeking strategic collaborations and licensing opportunities to accelerate the development and commercialization of CM-101. Their commitment to developing effective treatments for these debilitating diseases has positioned them as a leading player in the fibro-inflammatory disease space.

Chemomab Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for fibro-inflammatory diseases with high unmet need. Their mission is driven by their discovery of the key role of the soluble protein CCL24 in promoting fibrosis and inflammation, leading to the development of CM-101, a first-in-class monoclonal antibody designed to neutralize CCL24 activity. They are committed to improving the quality of life for patients suffering from debilitating and life-threatening diseases by translating novel biological insights into transformative treatments.

Chemomab Therapeutics promotes a culture of innovation, evidence-driven research, and a strong commitment to improving the lives of patients. Their vision emphasizes translating novel biological insights into transformative treatments, built upon a deep understanding of fibro-inflammatory mediators and pathways. The company values collaboration, both within the organization and with leading researchers worldwide, fostering a dynamic and results-oriented environment.